MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences Corporation (NASDAQ: EXAS) today announced the publication in the Annals of Internal Medicine the findings of a National Institutes of Health-funded multi-center study led by Dr. David Ahlquist of the Mayo Clinic. The study tested the performance of early generation stool-based DNA (sDNA) screening technologies for the detection of colorectal cancer and pre-malignant polyps, in stool specimens that were not buffer stabilized, as in the current commercial version. The findings demonstrate the important clinical potential of sDNA technology in detecting both colorectal cancer and significant pre-malignant polyps in the screening setting and demonstrate the performance advantages of sDNA screening over fecal occult blood testing for the detection of pre-malignant polyps. These data, which have been previously disclosed at national meetings over the years, utilized versions of the Company’s technologies that are not as advanced as those commercially offered today. sDNA technology has been included in the American Cancer Society and US Multi-Society Task Force guidelines for Colorectal Cancer Screening. Current colorectal cancer screening guidelines emphasize detection of precancerous polyps—today the province solely of invasive techniques like colonoscopy—as the most effective strategy for preventing deaths from colon cancer.
